MaxCyte Q1 2024 GAAP EPS $(0.09) Beats $(0.12) Estimate, Sales $11.342M Beat $7.462M Estimate
$MXCT
Biotechnology: Commercial Physical & Biological Resarch
Health Care
MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.12) by 25 percent. This is a 18.18 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $11.342 million which beat the analyst consensus estimate of $7.462 million by 52.00 percent. This is a 32.25 percent increase over sales of $8.576 million the same period last year.